The proton-pump inhibitors: Similarities and differences

Clinical Therapeutics

Volumn 22, Issue 3, 2000, Pages 266-280

  Horn, John ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acid related disease; Gastroesophageal reflux disease; Peptic ulcer disease; Proton pump inhibitors

Indexed keywords

DIAZEPAM; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

BARRETT ESOPHAGUS; CLINICAL PHARMACOLOGY; DATA BASE; DRUG CHOICE; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DUODENUM ULCER; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; MAINTENANCE THERAPY; PEPTIC ULCER; RECURRENT PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; STOMACH ULCER; ULCER HEALING; ZOLLINGER ELLISON SYNDROME;

EID: 0034005344     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80032-6     Document Type: Article

References (52)

1. 1. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997; 17:22-37.
2. + ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.
3. 3. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol. 1991;42: 321-328.
4. 4. Williams MP, Pounder RE. The pharmacology of rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):3-10.
5. 5. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272:22,438-22,446.
6. 6. Huang JQ, Hunt RH. pH. healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996;69:159-174.
7. 7. Goldberg HI, Dodds WJ, Gee S, et al. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969;56: 223-230.
8. 8. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12: 1079-1089.
9. 9. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs. 1996;51:460-482.
10. 10. Langtry HD, Wilde MI. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997;54: 473-500.
11. 11. Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995;36:539-543.
12. 12. Koop H, Kuly S, Flüg M, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol. 1996;8:915-918.
13. 13. Verdú EF, Armstrong D, Idström J-P, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut. 1995;37:743-748.
14. 14. Smout AJPM. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent? Scand J Gastroenterol. 1998;33(Suppl 225):32-35.
15. 15. Bell NV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59-67.
16. 16. Robinson M, Maton PN, Rodriguez S, et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997;11:973-980.
17. 17. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13:49-57.
18. 18. Mössner J, Hölscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial. Aliment Pharmacol Ther. 1995;9:321-326.
19. 19. Birbara C, Breiter J, Collins D, et al. Rabeprazole: Preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD. Am J Gastroenterol. 1998;93:1630. Abstract.
20. 20. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther. 1990;4:25-33.
21. 21. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.
22. 22. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer: A European multicentre study. Aliment Pharmacol Ther. 1998;12:789-795.
23. 23. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345-351.
24. 24. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150mg bid in the healing of active duodenal ulcer. Gastroenterology. 1997;112:A154. Abstract.
25. 25. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. Aliment Pharmacol Ther. 1999;13:179-186.
26. 26. Hirschowitz BI. Zollinger-Ellison syndrome: Pathogenesis, diagnosis, and management. Am J Gastroenterol. 1997;92 (Suppl 4):44S-50S.
27. 27. Qureshi W, Rashid S. Zollinger-Ellison syndrome: Improved treatment options for this complex disorder. Postgrad Med. 1998;104:155-158,163-164.
28. 28. Maton PN. Zollinger-Ellison syndrome: Recognition and management of acid hypersecretion. Drugs. 1996;52:33-44.
29. 29. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1991;36: 394-404.
30. 30. Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther. 1996;10:507-522.
31. 31. Mignon M, Merrouche M, Gardner J, et al. Rabeprazole therapy effective in Zollinger-Ellison syndrome and idiopathic gastric acid hypersecretion. Gastroenterology. 1999;116:A253. Abstract.
32. 32. Cameron AJ. Management of Barrett's esophagus. Mayo Clin Proc. 1998;73: 457-461.
33. 33. Bremner CG, Bremner RM. Barrett's esophagus. Surg Clin North Am. 1997;77: 1115-1137.
34. 34. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's esophagus during omeprazole treatment: A randomized double blind study. Gut. 1999; 45:489-494.
35. 35. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther. 1999;13:1205-1209.
36. 36. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65-69.
37. 37. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: The Maastricht Consensus Report. Gut. 1997;41:8-13.
38. 38. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21-27.
39. 39. Hirai M, Azuma T, Ito S, et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol. 1995;30:461-464.
40. 40. Tsuchiya M, Imamura L, Park J-B, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995;18:1053-1056.
41. 41. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology. 1994;107:738-743.
42. 42. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993;88:1801-1802. Letter.
43. 43. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol. 1998;93:1909-1913.
44. 44. Chu K-M, Choi H-K, Tuen HH, et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. Am J Gastroenterol. 1998;93:1436-1442.
45. 45. Schwartz H, Krause R, Sahba B, et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: A randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol. 1998;93:584-590.
46. 46. Adamek RJ, Bethke TD, and the International Pantoprazole HP Study Group. Cure of Helicobacter pylori infection and healing of duodenal ulcer: Comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. Am J Gastroenterol. 1998;93:1919-1924.
47. 47. Louw JA, Van Rensburg CJ, Hanslo D, et al. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. Aliment Pharmacol Ther. 1998;12:545-550.
48. 48. Pazzi P, Scagliarini R, Gamberini S, et al. Short-term, low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther. 1998;12:731-734.
49. 49. Korman MG, Bolin TD, Nicholson FB, Engelman JL. Lansoprazole quadruple therapy is effective in curing Helicobacter pylori. Helicobacter. 1998;3:202-205.
50. 50. Langtry HD, Wilde MI. Omeprazole: A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by non-steroidal anti-inflammatory drugs. Drugs. 1998;56:447-486.
51. 51. Mears JM, Kaplan B. Proton pump inhibitors: New drugs and indications. Am Fam Phys. 1996;53:285-292.
52. 52. Humphries T. A review of the drug-drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. Digestion. 1998;59(Suppl):76. Abstract.